What's Shaping Auna S.A.'s Positive EBITDA Target in 2026?

Auna's Q4 2025 adjusted EBITDA fell 14% FX-neutral, with margin contracting 4.5 percentage points to 19.5%, as Peru improved 14% in local currency but Colombia fell 25% and Mexico dropped 36%. The company nonetheless expects 12% FX-neutral EBITDA growth, helped by stronger Mexico operations, a strengthened capital structure, and the completed $825 million refinancing that lowered interest expense and extended maturities. Free cash flow rose 35% versus 2024.

Analysis

AUNA’s setup is less about the latest EBITDA wobble and more about whether the mix shift in Mexico is a real inflection or just a temporary reset after restructuring. The refinancing matters because it changes the equity story from a stressed deleveraging trade to a cash-yield recovery trade: lower near-term interest burden plus better local-currency funding reduces the probability that operating noise leaks into covenant or liquidity overhang. That usually compresses downside volatility before it meaningfully rerates the multiple.

The biggest second-order read-through is competitive. If Mexico can keep gaining preferred-provider placement and package penetration in out-of-pocket, AUNA is likely taking share from smaller regional operators that lack capex, payer, and systems scale. The winner is not just AUNA; it is also local suppliers of medical equipment and services tied to higher utilization, while standalone clinics and hospitals with weaker payer access likely face margin pressure as pricing discipline tightens.

The market is likely underestimating how long it takes for the Mexico recovery to show up in reported numbers: contract wins and oncology integration can improve volume quickly, but EBITDA lags as onboarding, mix, and admin normalization work through the P&L. The near-term risk is that Peru and Colombia softness masks Mexico improvement for another 1-2 quarters, creating a value trap if investors focus on consolidated margin compression rather than segment-level momentum. A sharper FX move or renewed inflation in imported medical inputs would be the main way the thesis gets delayed.

Contrarian view: the stock may deserve some multiple support despite flat estimates because the cleaner capital structure changes the equity duration. The more interesting debate is whether the current discount already prices a normal recovery in Mexico; if so, the trade becomes one of execution quality, not cheapness. That argues for expressing the view with defined risk rather than outright beta exposure.

Key Decisions for Investors

• Long AUNA common on a 3-6 month horizon if entry is near current levels; reward is a rerating from distressed/repair multiple toward a recovery multiple as Mexico throughput and cash flow visibility improve, with downside capped by the refinancing de-risking the balance sheet.
• Buy AUNA call spreads 6-9 months out instead of stock if volatility is cheap; this captures a delayed Mexico inflection while limiting exposure to another 1-2 quarters of consolidated margin noise.
• Pair trade: long AUNA / short a basket of lower-quality LATAM healthcare operators exposed to payer mix and FX leakage, to isolate the balance-sheet and Mexico-share-gain thesis from regional macro risk.
• If the stock rallies on headline guidance alone, trim into strength and re-enter after the next quarterly print; the main risk is front-running of the recovery before operating evidence catches up.